BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE

被引:0
|
作者
KITAGAWA, M
OKABE, T
OGINO, H
MATSUMOTO, H
SUZUKITAKAHASHI, I
KOKUBO, T
HIGASHI, H
SAITOH, S
TAYA, Y
YASUDA, H
OHBA, Y
NISHIMURA, S
TANAKA, N
OKUYAMA, A
机构
[1] MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN
[2] NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN
[3] KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.
引用
收藏
页码:2425 / 2432
页数:8
相关论文
共 50 条
  • [41] Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias
    Tibes, R.
    McDonagh, K. T.
    Lekakis, L.
    Bogenberger, J. M.
    Kim, S.
    Frazer, N.
    Mohrland, S.
    Bassett, D.
    Garcia, R.
    Schroeder, K.
    Shanmugam, V.
    Carpten, J.
    Hagelstrom, R. T.
    Beaudry, C.
    Von Hoff, D.
    Shea, T. C.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 389 - 396
  • [42] Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias
    R. Tibes
    K. T. McDonagh
    L. Lekakis
    J. M. Bogenberger
    S. Kim
    N. Frazer
    S. Mohrland
    D. Bassett
    R. Garcia
    K. Schroeder
    V. Shanmugam
    J. Carpten
    R. T. Hagelstrom
    C. Beaudry
    D. Von Hoff
    T. C. Shea
    Investigational New Drugs, 2015, 33 : 389 - 396
  • [43] Efficient production of cloned bovine embryos using cdc2 kinase inhibitor
    Yoo, JG
    Choe, SY
    Rho, GJ
    REPRODUCTION IN DOMESTIC ANIMALS, 2003, 38 (06) : 444 - 450
  • [44] Nuclear import of Cdk/cyclin complexes: Identification of distinct mechanisms for import of Cdk2/cyclin E and Cdc2/cyclin B1
    Moore, JD
    Yang, J
    Truant, R
    Kornbluth, S
    JOURNAL OF CELL BIOLOGY, 1999, 144 (02): : 213 - 224
  • [45] Synthesis and biological evaluation of analogues of butyrolactone I and molecular model of its interaction with CDK2
    Braña, MF
    García, ML
    López, B
    de Pascual-Teresa, B
    Ramos, A
    Pozuelo, JM
    Domínguez, MT
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2004, 2 (13) : 1864 - 1871
  • [46] Phosphorylation of synthetic peptides containing proline homologs by cdc2 kinase or cdk5
    Ando, S
    Ikuhara, T
    Kamata, T
    Sasaki, Y
    Hisanaga, S
    Kishimoto, T
    Ito, H
    Inagaki, M
    PEPTIDE SCIENCE - PRESENT AND FUTURE, 1999, : 364 - 366
  • [47] DEPHOSPHORYLATION OF CDC2 ON THREONINE-161 IS REQUIRED FOR CDC2 KINASE INACTIVATION AND NORMAL ANAPHASE
    LORCA, T
    LABBE, JC
    DEVAULT, A
    FESQUET, D
    CAPONY, JP
    CAVADORE, JC
    LEBOUFFANT, F
    DOREE, M
    EMBO JOURNAL, 1992, 11 (07): : 2381 - 2390
  • [48] An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells
    Wada, M
    Hosotani, R
    Lee, JU
    Doi, R
    Koshiba, T
    Fujimoto, K
    Miyamoto, Y
    Tsuji, S
    Nakajima, S
    Okuyama, A
    Imamura, M
    ANTICANCER RESEARCH, 1998, 18 (4A) : 2559 - 2566
  • [49] IDENTIFICATION OF THE DOMAINS IN CYCLIN-A REQUIRED FOR BINDING TO, AND ACTIVATION OF, P34(CDC2) AND P32(CDK2) PROTEIN-KINASE SUBUNITS
    KOBAYASHI, H
    STEWART, E
    POON, R
    ADAMCZEWSKI, JP
    GANNON, J
    HUNT, T
    MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (11) : 1279 - 1294
  • [50] Cdk2: A genuine protein kinase client of Hsp90 and Cdc37
    Prince, T
    Sun, L
    Matts, RL
    BIOCHEMISTRY, 2005, 44 (46) : 15287 - 15295